BENGALURU: Johnson & Johnson (J&J) said on Tuesday that it was in talks with the Indian government to explore ways to speed up delivery of its singleshot Covid-19 vaccine in the country. The company also said as per a recent announcement by the Indian drug regulator, there is no longer a need to conduct bridging clinical trials of the vaccines in India.
The US-based company said in April it was seeking an approval to conduct a bridging clinical study of its Janssen Covid-19 vaccine candidate in India. In May, however, the country scrapped local trials for “well-established” vaccines manufactured in other countries.
Meanwhile, an NGO, the Association of Healthcare Providers (AHPI), said that it was planning to procure 100 million doses of the Johnson-&Johnson vaccine from the European Union (EU) to be administered in India.
“We as an NGO are representing a vast majority of hospitals and have given a letter of intent to have 100 million doses for India. It is currently being processed,” director general of AHPI, Dr Girdhar Gyani said.
The US-based company said in April it was seeking an approval to conduct a bridging clinical study of its Janssen Covid-19 vaccine candidate in India. In May, however, the country scrapped local trials for “well-established” vaccines manufactured in other countries.
Meanwhile, an NGO, the Association of Healthcare Providers (AHPI), said that it was planning to procure 100 million doses of the Johnson-&Johnson vaccine from the European Union (EU) to be administered in India.
“We as an NGO are representing a vast majority of hospitals and have given a letter of intent to have 100 million doses for India. It is currently being processed,” director general of AHPI, Dr Girdhar Gyani said.
More News
Number of tests by 2 private labs at Mohalla clinics sees 80% dip since ACB report | India News – Times of India
Adhir Chowdhury Reveals Why Congress Attacks Adani-Ambani; BJP Hits Back
Murder convict gets furlough, victim’s kin move Supreme Court | India News – Times of India